ENLV Stock Summary and Trading Ideas (Enlivex Therapeutics Ltd. - | NASDAQ:ENLV)

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Enlivex Therapeutics Ltd. - trades on the NASDAQ stock market under the symbol ENLV.

As of February 9, 2026, ENLV stock price declined to $1.15 with 311,556 million shares trading.

ENLV has a beta of 0.67, meaning it tends to be less sensitive to market movements. ENLV has a correlation of 0.01 to the broad based SPY ETF.

ENLV has a market cap of $272.99 million. This is considered a Small Cap stock.

In the last 3 years, ENLV traded as high as $4.65 and as low as $.66.

The top ETF exchange traded funds that ENLV belongs to (by Net Assets): QQQS.

ENLV has underperformed the market in the last year with a return of +11.7%, while SPY returned +15.9%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ENLV shares. However, ENLV has outperformed the market in the last 3 month and 2 week periods, returning +13.9% and +6.5%, while SPY returned +4.0% and +0.9%, respectively. This indicates ENLV has been having a stronger performance recently.

ENLV support price is $1.09 and resistance is $1.23 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ENLV shares will trade within this expected range on the day.